Vimian Group has acquired two product portfolios of veterinary surgical instruments and orthopedic implants in the US. The acquisition marks the entry into a new product category with veterinary surgical instrumentation and expands Vimian’s portfolio of high-quality orthopedic implants for companion animals. The acquired portfolios have combined annual revenues of around USD 6.5 million.
Vimian Group’s MedTech segment, Movora, has acquired two product portfolios of veterinary surgical instruments and orthopedic implants sold to veterinary clinics across North America under the brands Spectrum and Everost. The acquisition is a carve-out from a healthcare company. The acquired portfolios include a wide range of high-quality veterinary orthopedic implants sold under the brand Everost as well as a broad offering of surgical instruments developed specifically for veterinary applications and sold under the brand Spectrum.
“This acquisition marks our entry into a new product category with veterinary surgical instrumentation and expands our portfolio of high-quality orthopedic implants. We gain access to a loyal customer base that we can leverage for our entire MedTech offering in the US and foresee significant synergy potential as we integrate these product portfolios into our commercial infrastructure around the world”, says Patrick Gendreau, Co-CEO of Vimian’s MedTech segment Movora.
The acquisition has a marginal impact on Vimian’s earnings per share and was consolidated into Vimian’s MedTech segment on 4 April, 2022.